Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.38

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned a consensus rating of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $34.38.

A number of equities research analysts recently weighed in on XNCR shares. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $11.51 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor has a one year low of $10.90 and a one year high of $27.24. The firm has a market capitalization of $811.02 million, a P/E ratio of -3.60 and a beta of 0.74. The company’s fifty day moving average is $15.72 and its two-hundred day moving average is $20.14.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Analysts forecast that Xencor will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Xencor

Hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC lifted its stake in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new position in Xencor in the 4th quarter valued at $34,000. GAMMA Investing LLC lifted its stake in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the period. KBC Group NV boosted its holdings in shares of Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares during the last quarter. Finally, Quarry LP grew its position in shares of Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 2,108 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.